

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/524,963	First Named Inventor: David William Tonge
371 Filing Date: February 18, 2005	Attorney Docket No.: 100815-1P US
Examiner: Leslie A. Royds	Group Art Unit: 1614
Customer No.: 44992	Confirmation No.: 3567
Title: N-(-3-METHOXY-5-METHYLPYRAZIN-2-YL)-2-(4'-1,3,4-OXADIAZOL-2-YL!PHENYL)PYRIDINE-3 SULPHONAMIDE AS AN ANTICANCER AGENT	

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT OF SUBSTANCE OF TELEPHONIC INTERVIEW**

Sir:

In response to the Interview Summary dated August 17, 2009, Applicants provide the following remarks that contain a statement of substance for the telephonic interview held on August 13, 2009.

**Remarks/Arguments** begin on page 2 of this paper.

## REMARKS/ARGUMENTS

In accordance with the request made in the Interview Summary dated August 17, 2009, and which request was confirmed in a second brief follow-up conversation on September 3, 2009, Applicants hereby confirm and acknowledge a telephonic interview with Examiner Royds regarding the outstanding objection to the oath/declaration. The substance of the telephonic interview tracked the substance of the line of reasoning introduced in the Preliminary Remarks section in Applicants' prior response of May 20, 2009 (page 5):

In addition, the Examiner has suggested that the oath/declaration filed February 18, 2005 is defective because the oath/declaration contains handwritten changes to the name of each inventor that have not been initialed or dated by the individual(s) who executed the declaration. Applicants disagree with this assessment, and enclose herewith the original patent application paperwork including the originally filed oath/declaration and the date-stamped postcard receipt as evidence of receipt of these documents. Applicants assert that such noted markings and "handwriting" was a product of the USPTO internal filing system and was not effected by Applicants.

However, solely for convenience Applicants provide herewith an additional copy of the originally submitted oath/declaration. It is Applicants contention that the attached copy should suffice as a replacement for the existing USPTO copy of the oath/declaration.

***Moreover, for the record, Applicants supplied the proper oath/declaration with the original application papers, and it was by USPTO error that markings were entered thereupon. As such, the attached copy of the original oath/declaration is solely for the convenience of the Office and the instant Examiner, and should not be considered a "supplemental oath/declaration."***

The Examiner acknowledged at this point that a convenience copy of the original oath/declaration would be sufficient to overcome the objection.

## CONCLUSION

Applicants again respectfully request favorable reconsideration of all outstanding rejections/objections. As noted in our prior response, if a telephone conversation with Applicants' attorney would help to expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' attorney at the telephone number below.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100815-1P US.

Respectfully submitted,

/Jacob G. Weintraub/

---

Name: Jacob G. Weintraub  
Dated: September 8, 2009  
Reg. No.: 56,469  
Phone No.: 1 781 839 4182  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 02451